解放军医学院学报
解放軍醫學院學報
해방군의학원학보
Academic Journal of Chinese Pla Medical School
2015年
11期
1085-1088
,共4页
王英哲%司文%令狐锐霞%张兴洋%吉铁凤%赵冬梅%杨俊兰
王英哲%司文%令狐銳霞%張興洋%吉鐵鳳%趙鼕梅%楊俊蘭
왕영철%사문%령호예하%장흥양%길철봉%조동매%양준란
转移性乳腺癌%药物疗法%卡培他滨%吉西他滨%长春瑞滨
轉移性乳腺癌%藥物療法%卡培他濱%吉西他濱%長春瑞濱
전이성유선암%약물요법%잡배타빈%길서타빈%장춘서빈
metastatic breast cancer%drug therapy%capecitabin%gemcitabine%vinorelbine
目的:观察吉西他滨或长春瑞滨联合卡培他滨方案治疗复发转移性乳腺癌患者的疗效。方法本研究纳入2008年1月1日-2014年5月1日解放军总医院收治的采用吉西他滨或长春瑞滨联合卡培他滨方案治疗的75例女性晚期乳腺癌患者,42例接受卡培他滨联合吉西他滨(GX)方案治疗,33例接受卡培他滨联合长春瑞滨(NX)方案治疗。结果 GX方案组客观有效率为16.7%,疾病控制率为85.7%,临床获益率为45.2%,肿瘤进展时间为5.68个月(95%CI:3.679~7.689);NX方案组客观有效率为29.3%,疾病控制率为74.8%,临床获益率为51.5%,肿瘤进展时间为8.25个月(95%CI:3.717~12.776), NX方案用于一线化疗疗效优于二线或以上化疗疗效。结论 NX方案在晚期患者的治疗中用于一线化疗疗效更佳;GX方案在后续多线化疗中也可取得较好疗效。
目的:觀察吉西他濱或長春瑞濱聯閤卡培他濱方案治療複髮轉移性乳腺癌患者的療效。方法本研究納入2008年1月1日-2014年5月1日解放軍總醫院收治的採用吉西他濱或長春瑞濱聯閤卡培他濱方案治療的75例女性晚期乳腺癌患者,42例接受卡培他濱聯閤吉西他濱(GX)方案治療,33例接受卡培他濱聯閤長春瑞濱(NX)方案治療。結果 GX方案組客觀有效率為16.7%,疾病控製率為85.7%,臨床穫益率為45.2%,腫瘤進展時間為5.68箇月(95%CI:3.679~7.689);NX方案組客觀有效率為29.3%,疾病控製率為74.8%,臨床穫益率為51.5%,腫瘤進展時間為8.25箇月(95%CI:3.717~12.776), NX方案用于一線化療療效優于二線或以上化療療效。結論 NX方案在晚期患者的治療中用于一線化療療效更佳;GX方案在後續多線化療中也可取得較好療效。
목적:관찰길서타빈혹장춘서빈연합잡배타빈방안치료복발전이성유선암환자적료효。방법본연구납입2008년1월1일-2014년5월1일해방군총의원수치적채용길서타빈혹장춘서빈연합잡배타빈방안치료적75례녀성만기유선암환자,42례접수잡배타빈연합길서타빈(GX)방안치료,33례접수잡배타빈연합장춘서빈(NX)방안치료。결과 GX방안조객관유효솔위16.7%,질병공제솔위85.7%,림상획익솔위45.2%,종류진전시간위5.68개월(95%CI:3.679~7.689);NX방안조객관유효솔위29.3%,질병공제솔위74.8%,림상획익솔위51.5%,종류진전시간위8.25개월(95%CI:3.717~12.776), NX방안용우일선화료료효우우이선혹이상화료료효。결론 NX방안재만기환자적치료중용우일선화료료효경가;GX방안재후속다선화료중야가취득교호료효。
Objective To evaluate the efficacy of gemcitabine/vinorelbine combined with capecitabin in treatment of patients with recurrent metastatic breast cancer.Methods Seventy-five patients diagnosed with recurrent metastatic breast cancer in Chinese PLA General Hospital from January 1, 2008 to May 1, 2014 were enrolled in this study. Of the 75 cases, 42 patients were treated with gemcitabine and capecitabin (GX), 33 patients were treated with vinorelbine and capecitabin (NX).Results In GX regimen group, the objective response rate was 16.7%, the disease control rate was 85.7%, the clinical benefit rate was 45.2%, and the time-to-progression was 5.68 (95%CI: 3.679-7.689) months. In NX regimen group, the objective response rate was 29.3%, the disease control rate was 74.8%, the clinical benefit rate was 51.5%, and the time-to-progression was 8.25 (95%CI: 3.717-12.776) months. The efficacy of NX regimen infirst-line chemotherapy was superior to multi-line chemotherapy. Conclusion Both treatments are well tolerated. NX regimen may have a better efficacy infirst-line chemotherapy.